Diabetic kidney disease: Act now or pay later? "World Kidney Day" March 11th 2010

Archivos de Cardiologia de Mexico

Volumn 80, Issue 1, 2010, Pages 44-47

  Atkins, Robert C ^a   Zimmet, Paul ^b  

^a ALFRED HOSPITAL   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIABETIC NEPHROPATHY; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVENTIVE HEALTH SERVICE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; RISK MANAGEMENT; COMPLICATION; DIABETIC NEPHROPATHIES; HEALTH PROMOTION; TIME;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEALTH PROMOTION; HUMANS; TIME FACTORS;

EID: 77952315642     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. International Diabetes Federation and International Society of Nephrology. Diabetes and kidney disease: Time to act 2003: Brussels.
2. Zimmet, P., K. Alberti, J. Shaw, Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-787. (Pubitemid 34000780)
3. King H, R. Aubert, W. Herman, Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-1431.
4. Yoon K, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368:1681-1688. (Pubitemid 46048556)
5. Sicree R, Shaw J, Zimmet P, Diabetes and impaired glucose tolerance. In: Diabetes Atlas, 3rd edition, D. Gan, Editor. International Diabetes Federation: Brussels 2006: 15-109.
6. Reutens AT, Prentice L, Atkins R. The Epidemiology of Diabetic Kidney Disease. In: The Epidemiology of Diabetes Mellitus, 2nd Edition, J. Ekoé, et al., Editors. John Wiley & Sons Ltd. Chichester 2008; 499-518.
7. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. International comparisons, in 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2007, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda. 239-254.
8. Appendix II, in ANZDATA Registry Report 2008, McDonald S, Excell L, Livingston B. Editors. 2008, Australia and New Zealand Dialysis and Transplant Registry: Adelaide. 1-97.
9. Yamagata K, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 2008;12:1-8.
10. Lysaght M, Maintenance dialysis population dynamics: Current trends and long term implications. J Am Soc Nephrol 2002; 13:S37-40.
11. Adler A, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225-232. (Pubitemid 35463925)
12. Retnakaran R, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55(6):1832-1839.
13. Parving H, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006; 69(11):2057-2063. (Pubitemid 43924271)
14. Ninomiya T, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20(8):1813-1821.
15. Dunstan D, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25(5):829-834.
16. White S, et al. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 2008;188(4):204-208.
17. Whaley-Connell A, et al., Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009; 53(4 Suppl 4):S11-21. (Pubitemid 351417308)
18. Thomas M, Viberti G., Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nat Clin Pract Nephrol 2008; 4(1):2-3.
19. Holman R, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359(15):1577-1589.
20. Bilous, R., Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008; 25(Suppl 2):p. 25-29
21. Gaede, P., et al., Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358(6):580-591 (Pubitemid 351214285)
22. Patel, A., et al., Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370:829-840 (Pubitemid 47362321)
23. Group), A.C., et al., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572 (Pubitemid 351831357)
24. Zoungas, S., et al., The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care 2009; Aug 3. [Epub ahead of print].
25. Ruggenenti P, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351(19):1941-1951
26. Parving H, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12):870-878.
27. Lewis E, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345:851-860.
28. Burney B, Kalaitzidis R, Bakris G, Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 2009; 18(2):107-111.